Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Tax Assets (2018 - 2021)

Historic Current Deferred Tax Assets for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Q3 2021 value amounting to $504522.0.

  • China SXT Pharmaceuticals' Current Deferred Tax Assets fell 487.39% to $504522.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $504522.0, marking a year-over-year decrease of 487.39%. This contributed to the annual value of $547807.0 for FY2021, which is 728.33% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Current Deferred Tax Assets stood at $504522.0 for Q3 2021, which was down 487.39% from $547807.0 recorded in Q1 2021.
  • Over the past 5 years, China SXT Pharmaceuticals' Current Deferred Tax Assets peaked at $547807.0 during Q1 2021, and registered a low of -$48454.0 during Q3 2018.
  • For the 3-year period, China SXT Pharmaceuticals' Current Deferred Tax Assets averaged around $408972.8, with its median value being $510617.0 (2020).
  • Over the last 5 years, China SXT Pharmaceuticals' Current Deferred Tax Assets had its largest YoY gain of 728.33% in 2021, and its largest YoY loss of 487.39% in 2021.
  • Over the past 3 years, China SXT Pharmaceuticals' Current Deferred Tax Assets (Quarter) stood at -$48454.0 in 2018, then soared by 1194.59% to $530372.0 in 2020, then fell by 4.87% to $504522.0 in 2021.
  • Its last three reported values are $504522.0 in Q3 2021, $547807.0 for Q1 2021, and $530372.0 during Q3 2020.